Company news

aTyr Pharma, Inc. news in 2025

aTyr Pharma, Inc.'s news releases, calls and decks from 2025, newest first.

View company

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference

November 10, 2025

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

November 6, 2025

aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025

September 30, 2025

Foundation for Sarcoidosis Research Reacts to the Announcement of aTyr Pharma’s Phase 3 Clinical Trial Results

September 17, 2025

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

September 15, 2025

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 5, 2025

aTyr Pharma Announces Second Quarter 2025 Results and Provides Corporate Update

August 7, 2025

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

July 22, 2025

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

June 26, 2025

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

June 4, 2025

aTyr Pharma to Present at Upcoming Investor Conferences

May 20, 2025

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

May 19, 2025

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

May 14, 2025

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

May 7, 2025

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

April 29, 2025

aTyr Pharma to Participate in April Investor Conferences

April 3, 2025

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

March 26, 2025

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

March 13, 2025

aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine

March 12, 2025

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

March 6, 2025

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

March 4, 2025

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

January 28, 2025

Decks in 2025